<DOC>
	<DOCNO>NCT01064453</DOCNO>
	<brief_summary>Angeliq regulatory Post-Marketing Surveillance ( PMS ) get data safety efficacy real practice indication approve Korea Food Drug Administration ( KFDA ) . This non-interventional , prospective , multi-center study.Target number patient 4500 .</brief_summary>
	<brief_title>Angeliq Regulatory Post Marketing Surveillance</brief_title>
	<detailed_description />
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Osteoporosis , Postmenopausal</mesh_term>
	<mesh_term>Drospirenone ethinyl estradiol combination</mesh_term>
	<criteria>Hormone replacement therapy estrogen deficiency symptom postmenopausal woman 1 year postmenopause Prevention osteoporosis postmenopausal woman high risk future fracture intolerant , contraindicate , medicinal product approve prevention osteoporosis Undiagnosed genital bleeding Known , past suspect cancer breast Known suspect estrogendependent malignant tumor ( e.g . endometrial cancer ) Untreated endometrial hyperplasia Previous idiopathic current venous thromboembolism ( e.g . deep venous thrombosis , pulmonary embolism ) Active recent arterial thromboembolic disease ( e.g . angina , myocardial infarction ) Acute liver disease , history liver disease long liver function test fail return normal Porphyria Severe renal insufficiency acute renal failure Known hypersensitivity active substance excipients</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2013</verification_date>
	<keyword>Menopause</keyword>
	<keyword>Menopausal symptom</keyword>
	<keyword>Prevention osteoporosis menopausal woman</keyword>
	<keyword>Estrogen deficiency symptom</keyword>
	<keyword>Hormone replacement therapy</keyword>
</DOC>